No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
DXR Daxor
- 9.650
- -0.030-0.31%
Trading May 1 11:34 ET
46.38MMarket Cap68.93P/E (TTM)
9.695High9.650Low4.65KVolume9.650Open9.680Pre Close44.91KTurnover0.22%Turnover Ratio68.93P/E (Static)4.81MShares13.12852wk High1.36P/B20.01MFloat Cap7.11052wk Low--Dividend TTM2.07MShs Float24.076Historical High--Div YieldTTM0.47%Amplitude3.400Historical Low9.661Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
New Studies Prove the Clinical Benefits of Daxor's Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Data Presented at the American College of Cardiology Scientific Sessions; Research Letter Published in the Prestigious American Heart Journal Oak Ridge, TN, April 16, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation
Daxor's Promising Growth and Innovation Outlook Merit a Buy Rating
Express News | Daxor Corp : Ascendiant Capital Markets Raises Target Price to $24.5 From $24
Daxor Corporation Announces New Hospital Account at Leading Chicago Hospital
450-Bed Hospital Purchases BVA-100 Blood Volume Analyzer to Launch Heart Failure Program Oak Ridge, TN, April 10, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood
Daxor Corporation to Exhibit at the American College of Cardiology for ACC.24
Oak Ridge, TN, April 01, 2024 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces it will be exhibiting at the American Col
Daxor Corporation (NASDAQ:DXR) Q4 2023 Earnings Call Transcript
Comments
$Daxor(DXR.US$
NEWS
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Daxor (Nasdaq: DXR) announces two new studies validating the clinical benefits of blood volume analysis (BVA) in ambulatory heart failure patients. The studies highlight the lack of correlation between surrogate measures and actual blood volume, emphasizing the importance of accurate volume measurement. Data presented at th...
NEWS
New Studies Prove the Clinical Benefits of Daxor’s Blood Volume (BVA-100TM) Diagnostic In Ambulatory Heart Failure Patients For Measurement of Congestion
Daxor (Nasdaq: DXR) announces two new studies validating the clinical benefits of blood volume analysis (BVA) in ambulatory heart failure patients. The studies highlight the lack of correlation between surrogate measures and actual blood volume, emphasizing the importance of accurate volume measurement. Data presented at th...
1
Future Movement the crucial last few months of the year
Hello everyone,
We're seeking community insights on the potential movement of this stock in the coming one to two months. Do you anticipate it to rise or fall?
If you have any solid ideas, insider information, or news that might influence this stock's direction, kindly share in the comments section below. Your input is greatly valued!
Thank you for your participation.
$Daxor(DXR.US$
We're seeking community insights on the potential movement of this stock in the coming one to two months. Do you anticipate it to rise or fall?
If you have any solid ideas, insider information, or news that might influence this stock's direction, kindly share in the comments section below. Your input is greatly valued!
Thank you for your participation.
$Daxor(DXR.US$
1
$Daxor(DXR.US$ slow and steady volume increase. Microfloat, lots of good news, will be a runner when she gets found
1
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg